University of Cambridge

Novo Nordisk Foundation: The revolution began at a local pub: now, the human genome can be read in just one hour

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Genomics, Health, The Prize, Survival, Disease, Panton Arms, Science, COVID-19, University, DSM-IV codes, Human, NGS, Research, DNA, Human genome, Cancer, Life, University of Cambridge, Prize, Genome, Novo Nordisk Foundation, USD, Paper, Pharmaceutical industry

Understanding the genetic basis for what makes us all unique, including disease-related aspects, requires sequencing of not just one, but many, human genomes.

Key Points: 
  • Understanding the genetic basis for what makes us all unique, including disease-related aspects, requires sequencing of not just one, but many, human genomes.
  • In 2000, one human genome took over 10 years to sequence at a cost of more than 1 billion dollars.
  • Their new technology means that a human genome can be sequenced in just one hour and for less than USD 1,000, meaning millions are sequenced each year.
  • For their pioneering efforts, Sir David Klenerman and Sir Shankar Balasubramanian are receiving the 2024 Novo Nordisk Prize.

Advancing PSP and CBD Research: CurePSP Announces Latest Pathway and Pipeline Grant Recipients

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Neuroscience, PSP, Mayo Clinic, Biomarker, University, CBD, University of Cambridge, Proteomics, Corticobasal degeneration, University of Edinburgh, UCLA, Medical device

NEW YORK, March 14, 2024 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants, totaling approximately $400,000.

Key Points: 
  • NEW YORK, March 14, 2024 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants, totaling approximately $400,000.
  • The studies will make progress in understanding the basic neurobiology of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and in developing biomarkers to improve diagnosis and treatment.
  • The newest Pipeline grants will fund two projects: "Blood-based Fingerprints of Neuroinflammation in People with PSP and CBD" by Dr. Maura Malpetti, and "Characterization of Plasma-derived Extracellular Vesicle Proteomics for Biomarker Development of PSP and CBD" by Dr. Yang You.
  • "There is a critical need to improve our understanding of PSP and CBD and to improve diagnosis, and these grants will help move the field forward."

Remarkable College Offers Arrive for Concordia International School Shanghai Class of 2024

Retrieved on: 
Thursday, March 14, 2024
University, UCL, Sport, G5, Ivy League, Concordian International School, News, QS, Cornell University, University of Cambridge, Student, Biology, Concordia International School Shanghai, School, Economics, Engineering, Babson College, Berklee College of Music, Management

SHANGHAI, March 14, 2024 /PRNewswire/ -- The Class of 2024 at Concordia International School Shanghai has demonstrated exceptional global achievements in this year's university admission season.

Key Points: 
  • SHANGHAI, March 14, 2024 /PRNewswire/ -- The Class of 2024 at Concordia International School Shanghai has demonstrated exceptional global achievements in this year's university admission season.
  • This year, Concordia's college acceptance rates rank among the highest of international schools in Shanghai, showcasing the students' dedication and Concordia's unwavering commitment to excellence.
  • Concordia International School Shanghai supports its high school students with comprehensive counseling services from grades 9-12, focusing on academic, social-emotional, career, as well as global perspective and identity development.
  • Congratulations to the remarkable seniors of Concordia International School Shanghai.

UNDER ARMOUR ANNOUNCES LEADERSHIP TRANSITION

Retrieved on: 
Wednesday, March 13, 2024
University of Cambridge, Growth, Allianz, Financial Times, Chairperson, University, Private sector, Bloomberg L.P., Athlete, Real-time, UAA, Queens' College, Cambridge, International Monetary Fund, PIMCO, Bangladesh Technical Education Board, Lauder, Marketing, Plank, Lead, Management

BALTIMORE, March 13, 2024 /PRNewswire/ -- Under Armour, Inc. (NYSE: UA, UAA) today announced that Kevin Plank will become President & Chief Executive Officer, effective April 1, 2024. Plank will succeed Stephanie Linnartz, who will be stepping down as President & Chief Executive Officer and member of the Board. In connection with Plank's appointment, Dr. Mohamed A. El-Erian, an independent director since 2018 and Lead Director since 2020, will become the non-executive Chair of the Board. Plank, who will transition from Executive Chair of the Board, will remain a director. Linnartz will remain an advisor to the company through April 30, 2024.

Key Points: 
  • Plank, who will transition from Executive Chair of the Board, will remain a director.
  • "On behalf of the full team, I want to thank Stephanie for her contributions to Under Armour.
  • "During her tenure, she strengthened the leadership team with executive hires in critical areas, including product, design, supply chain, consumer connectivity, and regional management.
  • Plank founded Under Armour in 1996, and since then, he has been the driving force behind its innovative products and brand.

ARIZONA VA AGENCY FINDS NO WRONGDOING IN AUDIT OF GRAND CANYON UNIVERSITY

Retrieved on: 
Monday, March 11, 2024
GCU, College, DPC, University of Cambridge, Organization, University, Federation, Ivy League, Georgetown University, Higher Learning Commission, Disclosure, Student, Provost, Deception, Supreme court, Grand Canyon University, Goldwater Institute, SAA, ED, Higher, Doctor, Supreme, NFL, Government, Harvard Law School, Federal Trade Commission, FTC, Nursing

PHOENIX, March 11, 2024 /PRNewswire/ -- The Arizona State Approving Agency (SAA) for the U.S. Department of Veterans Affairs has closed its most recent risk-based audit of Grand Canyon University with no findings.

Key Points: 
  • PHOENIX, March 11, 2024 /PRNewswire/ -- The Arizona State Approving Agency (SAA) for the U.S. Department of Veterans Affairs has closed its most recent risk-based audit of Grand Canyon University with no findings.
  • In a letter to GCU dated Feb. 21, the Arizona SAA stated it "did not have any substantiated findings based on our review of Grand Canyon University."
  • Further, the SAA stated, "There are no findings impacting the continued approval of Grand Canyon University at this time."
  • The SAA site visit also included reviews of specific areas relating to finances, enrollment, recruiting, student outcomes and other success measures.

Isabel Schnabel: R(ising) star?

Retrieved on: 
Wednesday, April 3, 2024
Reproduction, Economy, Faculty, Shousha, Journal of Economic Perspectives, Frankfurt, Climate, Second, Goodhart, History, BIS, Fit, Del Negro, Life expectancy, DFR, Investment, International Renewable Energy Agency, European Commission, USD, International economics, Policy, Corporation, Journal of International Economics, Speech, Black, Industrial Revolution, Innovation, IRENA, ECB, Observation, Communication, University of Cambridge, Zombie, International Monetary Fund, MIT Press, Watcher, Ferreira, Black Death, Canadian International Council, Federal, NBER, Weather, Federal Reserve Bank, Climate change, Longevity, Green, COVID-19, Intelligence, Spitzer, European University Institute, Journal, Research, Harvard Business School, SMA, University, Private sector, EMU, Education minister, Literature, Retirement, EIB, Bank of England, Feedback, Financial economics, Quarterly Journal of Economics, European Central Bank, The, Civil service commission, Uncertainty, Conference, Pressure, Faculty (division), Growth, Journal of Financial Economics, MIT, Anatomy, Society, Bank, Revolution, Quarterly Review, Productivity, IMF, Federal Reserve, Thought, Working paper, Rogoff, Renewable energy

This box investigates how households have responded to the 2021-23 inflationary episode using evidence from the ECB’s Consumer Expectations Survey.

Key Points: 
  • This box investigates how households have responded to the 2021-23 inflationary episode using evidence from the ECB’s Consumer Expectations Survey.
  • The findings suggest that households have primarily adjusted their consumption spending to cope with higher inflation.

Xometry Appoints James Miln as New Chief Financial Officer

Retrieved on: 
Thursday, February 29, 2024
Miln, CGMA, Yahoo!, University of Cambridge, Rallo, XMTR, Growth, Retirement, Advertising, ACMA, Brexit, EBay, IRC

A veteran of big-name tech and consumer brands, Miln brings considerable financial planning, operational and investor relations expertise to Xometry.

Key Points: 
  • A veteran of big-name tech and consumer brands, Miln brings considerable financial planning, operational and investor relations expertise to Xometry.
  • Miln succeeds retiring CFO Jim Rallo, who will remain as an advisor with Xometry through April.
  • Rallo will work closely with Miln and the rest of the leadership team to ensure a smooth transition.
  • “James’ significant experience across marketplaces, search and advertising will help us capitalize on our leadership position in digitizing manufacturing,” said Randy Altschuler, Chief Executive Officer of Xometry.

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024

Retrieved on: 
Monday, March 4, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Master of Science, Quality of life, Hospital, University of Cambridge, MT-ND4, University, LHON, Patient

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Honolulu, Hawaii (March 2-7, 2024).

Key Points: 
  • GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Honolulu, Hawaii (March 2-7, 2024).
  • Leading Leber Hereditary Optic Neuropathy (LHON) Key Opinion Leaders will provide updates on evidence related to the contralateral effect, on real-world experience with LUMEVOQ®, and on the comparison between LHON natural history, idebenone and LUMEVOQ®.
  • Poster presentation: “Lenadogene nolparvovec gene therapy improves visual recovery more than idebenone in m.11778G>A MT-ND4 LHON, and both treatments exceed the natural course of the disease”
    Presenter: Nancy J. Newman, MD, Emory University School of Medicine, Atlanta, Georgia, USA
    In addition, Benson S. Chen, MBChB, MSc, FRACP, Department of Clinical Neurosciences, University of Cambridge and Cambridge Eye Unit, Addenbrooke’s Hospital, United Kingdom, will present evidence on the quality of life of LHON patients in a platform presentation.
  • Platform presentation: “Vision-Related Quality of Life in LHON Patients Treated with Lenadogene Nolparvovec Gene Therapy: Analysis of the VFQ-25 Using Rasch Measurement Theory”

ATLAS OCEAN VOYAGES INTRODUCES NEW CULTURAL EXPEDITION PROGRAMMING FOR 2024

Retrieved on: 
Thursday, March 7, 2024
Museum, Social work, Royal Horticultural Society, Architecture, Doctor of Philosophy, Royal, Culture, Medical microbiology, Scott Polar Research Institute, University, RSPB, Religious broadcasting, Victoria and Albert Museum, Fossil, Local government, Atlas, British Museum, Fellow, Plant, University of Leicester, MBA, Radio, Gardening, BBC, Economics, Disabled parking permit, Environmental science, Education, Pepperdine University, FPV, Pritikin diet, Life, American Red Cross, Physics, Exploration, Research, Collection, Politics, Royal Society, University of Cambridge, Radio 4, Arawak, Emeritus, Imperial College London, Carib, WSI, Geological Society of London, UC, Emmanuel College, RHS, Tourism

FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season. An addition to the company's year-round expeditions that include Polar and Epicurean Expeditions, these new programs enhance appreciation for a variety of captivating regions and local cultures.

Key Points: 
  • FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season.
  • Atlas Ocean Voyages Cultural Expeditions include onboard and onshore programming focused on drone and photo workshops, cooking culture, and destination experts.
  • Below is an overview for 2024:
    Guests will embark on an exhilarating journey exclusively with Atlas Ocean Voyages Cultural Expeditions' new Atlas Focus Lab: Drone & Photo Workshops.
  • Combining an intimate and luxurious environment with genuine hospitality, Atlas Ocean Voyages ensures that each journey is a once-in-a-lifetime expedition.

Clarivate and Exor Sign Agreement Under Which Suzanne Heywood Will Be Nominated to Stand for Election to the Company's Board of Directors

Retrieved on: 
Monday, March 4, 2024
Annual general meeting, Doctor of Philosophy, University of Cambridge, McKinsey & Company, Iveco, HM Treasury, Partnership, Christian Louboutin, University of Oxford, CLVT, Science, Economist, CNH Industrial, AEX, Management

LONDON and AMSTERDAM, March 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence and Exor N.V. (AEX: EXO), the Netherlands-based diversified holding company, today announced that Suzanne Heywood will be nominated for election to the Clarivate Board of Directors at the Company's next Annual General Meeting of shareholders on May 7, 2024. Under the terms of the agreement, Exor, which now owns 10.1% of Clarivate, may increase its participation up to 17.5% of Clarivate's outstanding ordinary share capital.

Key Points: 
  • Under the terms of the agreement, Exor, which now owns 10.1% of Clarivate, may increase its participation up to 17.5% of Clarivate's outstanding ordinary share capital.
  • Jonathan Gear, CEO, Clarivate said: "We welcome Exor's commitment to our strategy as a long-term investor.
  • Andy Snyder, Chairman of the Board, Clarivate, commented: "We look forward to Suzanne joining the Board.
  • Suzanne Heywood is the COO of Exor and the Chair of CNH Industrial N.V. and Iveco Group.